Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Once-daily oral peptide shows comparable glycemic control to injectable benchmark in a short Phase 2 dose-ranging study.
Expanded liquid biopsy panel detects minimal residual disease earlier post-surgery, guiding adjuvant therapy decisions.
CNS-delivered antisense oligonucleotide improves motor function endpoints in a compassionate-use case series.
Heterologous booster strategy improves antibody durability in an immunogenicity follow-up study.
Hybrid tele-rehab program improves 6‑minute walk distance and fatigue scores in a controlled program evaluation.